Transcription factor E2F3 overexpressed in prostate cancer independently predicts clinical outcome - PubMed (original) (raw)
. 2004 Aug 5;23(35):5871-9.
doi: 10.1038/sj.onc.1207800.
Alison Falconer, Andrew R Dodson, Andrew R Norman, Nening Dennis, Anne Fletcher, Christine Southgate, Anna Dowe, David Dearnaley, Sameer Jhavar, Rosalind Eeles, Andrew Feber, Colin S Cooper
Affiliations
- PMID: 15184867
- DOI: 10.1038/sj.onc.1207800
Transcription factor E2F3 overexpressed in prostate cancer independently predicts clinical outcome
Christopher S Foster et al. Oncogene. 2004.
Abstract
E2F transcription factors, including E2F3, directly modulate expression of EZH2. Recently, overexpression of the EZH2 gene has been implicated in the development of human prostate cancer. In tissue microrarray studies we now show that expression of high levels of nuclear E2F3 occurs in a high proportion (98/147, 67%) of human prostate cancers, but is a rare event in non-neoplastic prostatic epithelium suggesting a role for E2F3 overexpression in prostate carcinogenesis. Patients with prostate cancer exhibiting immunohistochemically detectable nuclear E2F3 expression have poorer overall survival (P=0.0022) and cause-specific survival (P=0.0047) than patients without detectable E2F3 expression. When patients are stratified according to the maximum percentage of E2F3-positive nuclei identified within their prostate cancers (up to 20, 21-40%, etc.), there is an increasingly significant association between E2F3 staining and risk of death both for overall survival (P=0.0014) and for cause-specific survival (P=0.0004). Multivariate analyses select E2F3 expression as an independent factor predicting overall survival (unstratified P=0.0103, stratified P=0.0086) and cause-specific survival (unstratified P=0.0288, stratified P=0.0072). When these results are considered together with published data on EZH2 and on the E2F3 control protein pRB, we conclude that the pRB-E2F3-EZH2 control axis may have a critical role in modulating aggressiveness of individual human prostate cancer.
Similar articles
- Nuclear overexpression of the E2F3 transcription factor in human lung cancer.
Cooper CS, Nicholson AG, Foster C, Dodson A, Edwards S, Fletcher A, Roe T, Clark J, Joshi A, Norman A, Feber A, Lin D, Gao Y, Shipley J, Cheng SJ. Cooper CS, et al. Lung Cancer. 2006 Nov;54(2):155-62. doi: 10.1016/j.lungcan.2006.07.005. Epub 2006 Aug 30. Lung Cancer. 2006. PMID: 16938365 - Amplification and overexpression of E2F3 in human bladder cancer.
Feber A, Clark J, Goodwin G, Dodson AR, Smith PH, Fletcher A, Edwards S, Flohr P, Falconer A, Roe T, Kovacs G, Dennis N, Fisher C, Wooster R, Huddart R, Foster CS, Cooper CS. Feber A, et al. Oncogene. 2004 Feb 26;23(8):1627-30. doi: 10.1038/sj.onc.1207274. Oncogene. 2004. PMID: 14716298 - E2F3 amplification and overexpression is associated with invasive tumor growth and rapid tumor cell proliferation in urinary bladder cancer.
Oeggerli M, Tomovska S, Schraml P, Calvano-Forte D, Schafroth S, Simon R, Gasser T, Mihatsch MJ, Sauter G. Oeggerli M, et al. Oncogene. 2004 Jul 22;23(33):5616-23. doi: 10.1038/sj.onc.1207749. Oncogene. 2004. PMID: 15122326 - HER2 expression and gene amplification in pT2a Gleason score 6 prostate cancer incidentally detected in cystoprostatectomies: comparison with clinically detected androgen-dependent and androgen-independent cancer.
Montironi R, Mazzucchelli R, Barbisan F, Stramazzotti D, Santinelli A, Scarpelli M, Lòpez Beltran A. Montironi R, et al. Hum Pathol. 2006 Sep;37(9):1137-44. doi: 10.1016/j.humpath.2006.04.004. Epub 2006 Jun 21. Hum Pathol. 2006. PMID: 16938518 - Activation of signal transducer and activator of transcription-5 in prostate cancer predicts early recurrence.
Li H, Zhang Y, Glass A, Zellweger T, Gehan E, Bubendorf L, Gelmann EP, Nevalainen MT. Li H, et al. Clin Cancer Res. 2005 Aug 15;11(16):5863-8. doi: 10.1158/1078-0432.CCR-05-0562. Clin Cancer Res. 2005. PMID: 16115927
Cited by
- Semen sEV tRF-Based Models Increase Non-Invasive Prediction Accuracy of Clinically Significant Prostate Cancer among Patients with Moderately Altered PSA Levels.
Ferre-Giraldo A, Castells M, Sánchez-Herrero JF, López-Rodrigo O, de Rocco-Ponce M, Bassas L, Vigués F, Sumoy L, Larriba S. Ferre-Giraldo A, et al. Int J Mol Sci. 2024 Sep 20;25(18):10122. doi: 10.3390/ijms251810122. Int J Mol Sci. 2024. PMID: 39337607 Free PMC article. - ZBTB7A as a novel vulnerability in neuroendocrine prostate cancer.
Bae SY, Bergom HE, Day A, Greene JT, Sychev ZE, Larson G, Corey E, Plymate SR, Freedman TS, Hwang JH, Drake JM. Bae SY, et al. Front Endocrinol (Lausanne). 2023 Mar 29;14:1093332. doi: 10.3389/fendo.2023.1093332. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37065756 Free PMC article. - Systematic Analysis of E2F Expression and Its Relation in Colorectal Cancer Prognosis.
Xu Z, Qu H, Ren Y, Gong Z, Ri HJ, Zhang F, Shao S, Chen X, Chen X. Xu Z, et al. Int J Gen Med. 2022 May 11;15:4849-4870. doi: 10.2147/IJGM.S352141. eCollection 2022. Int J Gen Med. 2022. PMID: 35585998 Free PMC article. - Identification of Candidate Genes Regulating Carcass Depth and Hind Leg Circumference in Simmental Beef Cattle Using Illumina Bovine Beadchip and Next-Generation Sequencing Analyses.
Bordbar F, Mohammadabadi M, Jensen J, Xu L, Li J, Zhang L. Bordbar F, et al. Animals (Basel). 2022 Apr 25;12(9):1103. doi: 10.3390/ani12091103. Animals (Basel). 2022. PMID: 35565529 Free PMC article. - Differential Expression of E2F Transcription Factors and Their Functional and Prognostic Roles in Human Prostate Cancer.
Han Z, Mo R, Cai S, Feng Y, Tang Z, Ye J, Liu R, Cai Z, Zhu X, Deng Y, Zou Z, Wu Y, Cai Z, Liang Y, Zhong W. Han Z, et al. Front Cell Dev Biol. 2022 Apr 21;10:831329. doi: 10.3389/fcell.2022.831329. eCollection 2022. Front Cell Dev Biol. 2022. PMID: 35531101 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical